Genzyme in the UK

Company Info

UK News

November 3, 2016
Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) to Begin in the UK
September 16, 2016
Data on Treatment Effects with Lemtrada® ▼(alemtuzumab) Over Six Years in People with Relapsing Remitting Multiple Sclerosis to be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London
1 August, 2016
Sanofi and Regeneron Announce EMA Acceptance for Review of Marketing Authorisation Application for Sarilumab
30 June, 2016
Myozyme® (alglucosidase alfa) Shortlisted for Prix Galien Real World Evidence Award
13 June, 2016
Patients in Scotland denied prostate cancer drug
May 26, 2016
Sanofi Genzyme launches new UK nurse education programme in multiple sclerosis to help improve patient care and service delivery
May 25, 2016
NICE recommends Jevtana® (cabazitaxel) to treat eligible patients with advanced prostate cancer
April 16, 2016
10-year follow-up data on Lemtrada® ▼(alemtuzumab) detailing clinical efficacy in people with relapsing-remitting multiple sclerosis (MS) to be presented at the American Academy of Neurology (AAN) 2016 Annual Meeting
February 29, 2016
Sanofi Genzyme Recognises 2016 International Rare Disease Day with Premiere of Expression of Hope film
January 13, 2016
Sanofi Genzyme Announces UK Recipient of 2015 Annual Patient Advocacy Leadership (PAL) Awards Programme
October 9, 2015
Genzyme Announces UK Opening of Expression of Hope Art Exhibition at Rare Diseases Conference
July 31, 2015
Response Giving, Oxford-based mental health charity, receives charitable donation from Genzyme UK & Ireland
February 26, 2015
Cure & Action for Tay-Sachs Foundation (CATS) announced UK winner of Genzyme Patient Advocacy Leadership (PAL) Award
August 11, 2014
Aubagio® (teriflunomide), 14 mg tablet, a once-daily oral treatment for people with active relapsing-remitting multiple sclerosis is now available in the Republic of Ireland
July 7, 2014
SMC says yes to Lemtrada®▼ (alemtuzumab) 12mg IV, a new treatment for adults with active relapsing remitting-multiple sclerosis (RRMS)
May 28, 2014
Lemtrada®▼ (alemtuzumab) 12mg IV, a new treatment for adults with active relapsing remitting multiple sclerosis (RRMS), is recommended by NICE and now available in England
April 15, 2014
Genzyme Supports International Pompe Day 2014
March 10, 2014
SMC says yes to Aubagio® (teriflunomide), a new once daily first-line oral treatment available for people with an active relapsing remitting form of MS
February 28, 2014
Genzyme Supports Rare Disease Day 2014
22 January 2014
NICE says yes to Aubagio® (teriflunomide), a new once daily first-line oral treatment available for people with an active relapsing remitting form of MS
December 18, 2013
Genzyme Announces UK Winner of 2013 Patient Advocacy Leadership (PAL) Awards
November 22, 2013
Genzyme Welcomes Publication of UK Strategy for Rare Disease
February 27, 2013
Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
December 10, 2012
Genzyme Receives European Label Expansion for Thyrogen
November 27, 2012
Genzyme Honours Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation
April 8, 2010
New ‘Stem Cell Mobilisation’ Therapy Recommended by the All Wales Medicines Strategy Group
March 4, 2010
Genzyme Corporation’s generous benefaction to enable the creation of a key clinical academic post for Multiple Sclerosis, Neuroimmunological Diseases
January 18, 2010
New ‘Stem Cell Mobilisation’ Technology Accepted For Use by the Scottish Medicines Consortium
July 3, 2009
Andrew Lansley MP, Shadow Secretary of State for Health, sees cutting edge biotech science at Genzyme Europe Research in Cambridge


  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Tel: +01865 405200
Fax: +01865 774172

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Tel: +01440 703522
Fax: +01440 716269